Biosimilar Update: EC Approves Stelara Biosimilar
The European Commission (EC) has approved the use of Celltrion’s SteQeyma (CT-P43), an ustekinumab biosimilar referencing Stelara, for the treatment of multiple chronic inflammatory diseases. SteQeyma, which targets interleukin (IL)-12 and IL-23 cytokines, is approved as a biologic therapy in gastroenterology, dermatology and rheumatology indications. The decision from the EC follows a positive opinion recommending […]